Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Income from Continuing Operations for 2 consecutive years, with 1864092.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 195.92% to 1864092.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 11937417.0, a N/A change, with the full-year FY2025 number at 6643141.0, up 51.41% from a year prior.
  • Income from Continuing Operations was 1864092.0 for Q4 2025 at Neuphoria Therapeutics, up from 9906504.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 11262161.0 in Q1 2025 to a low of 15157166.0 in Q2 2025.